Boosting PD-1 blockade cancer immunotherapy by modulating T cell metabolism
| Project/Area Number |
17F17119
|
|---|
| Research Category |
Grant-in-Aid for JSPS Fellows
|
| Allocation Type | Single-year Grants |
|---|
| Section | 外国 |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Kyoto University |
|---|
| Host Researcher |
本庶 佑 京都大学, 高等研究院, 特別教授 (80090504)
|
|---|
| Foreign Research Fellow |
CHOWDHURY PARTHA 京都大学, 高等研究院, 外国人特別研究員
|
|---|
| Project Period (FY) |
2017-04-26 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2018: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2017: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | cancer immunotherapy / PD-1 blockade |
|---|
| Outline of Annual Research Achievements |
Recently blockade of a key negative regulator (PD-1) of immune system using antibody has led to a paradigm shift in the field of cancer drug discovery, owing to its durable effect against a wide variety of cancers and is termed as PD-1 blockade cancer immunotherapy. However, a substantial number of patients do not respond to this therapy. Thus, combination therapy to improve PD-1 blockade efficacy must be developed. To overcome the low response rate of PD-1 blockade therapy, various combinations have been used. But, many clinical trial reports have not shown encouraging results. We recently demonstrated that activation of PGC-1α, a key regulator of mitochondrial biogenesis, /peroxisome proliferator-activated receptors (PPARs) by bezafibrate improves the efficacy of PD-1 blockade. However, the mechanism of anti-tumor immunity development by activation of the PPAR pathway remains unknown. In this study, we investigated the effect of bezafibrate on phenotype of effector T cells and its mitochondrial activities followed by investigation of the molecular mechanism of how bezafibrate modulates the differentiation of CTLs and enhances T cell-based anti-tumor immunity. We found that bezafibrate upregulates fatty acid oxidation and inhibits the apoptosis of effector T cells. This effect of bezafibrate on the effector phase resulted in an increased number of effector T cells and augmentation of tumoricidal effect by PD-1 blockade. Therefore, PPAR signal activation in T cells may be a promising strategy for PD-1 blockade combination therapy.
|
| Research Progress Status |
平成30年度が最終年度であるため、記入しない。
|
| Strategy for Future Research Activity |
平成30年度が最終年度であるため、記入しない。
|
Report
(2 results)
Research Products
(3 results)
